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SUMMARY  22 
The identification of lymphocyte subsets with non-overlapping 23 
effector functions has been pivotal to the development of targeted 24 
therapies in immune mediated inflammatory diseases (IMIDs)1,2. 25 
However it remains unclear whether fibroblast subclasses with non-26 
overlapping functions also exist and are responsible for the wide 27 
variety of tissue driven processes observed in IMIDs such as 28 
inflammation and damage3-5. Here we identify and describe the biology 29 
of distinct subsets of fibroblasts responsible for mediating either 30 
inflammation or tissue damage in arthritis. We show that deletion of 31 
FAPα+ fibroblasts suppressed both inflammation and bone erosions in 32 
murine models of resolving and persistent arthritis. Single cell 33 
transcriptional analysis identified two distinct fibroblast subsets 34 
within the FAPα+ population: FAPα+ THY1+ immune effector 35 
fibroblasts located in the synovial sub-lining, and FAPα+ THY1- 36 
destructive fibroblasts restricted to the synovial lining layer. When 37 
adoptively transferred into the joint, FAPα+ THY1- fibroblasts 38 
selectively mediate bone and cartilage damage with little effect on 39 
inflammation, whereas transfer of FAPα+ THY1+ fibroblasts  resulted in 40 
a more severe and persistent inflammatory arthritis, with minimal 41 
effect on bone and cartilage. Our findings describing anatomically 42 
discrete, functionally distinct fibroblast subsets with non-overlapping 43 
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functions have important implications for cell based therapies aimed 44 
at modulating inflammation and tissue damage.  45 
Non-hematopoietic, tissue resident fibroblasts, contribute to the 46 
pathogenesis of many diseases and are known to develop epigenetically 47 
imprinted, site and disease specific phenotypes6-8. Rheumatoid arthritis 48 
(RA) is a prototypic IMID6 in which synovial fibroblasts (SFs) contribute to 49 
both joint damage7,8 and inflammation9. We found that expression of 50 
fibroblast activation protein α (FAPα), a cell membrane dipeptidyl 51 
peptidase10, was significantly higher in both synovial tissue and cultured 52 
SFs isolated from patients who fulfilled classification criteria for RA, 53 
compared to patients in whom joint inflammation resolved (Fig 1a,b,c), 54 
suggesting that FAPα expression may associate with a pathogenic 55 
fibroblast phenotype.  56 
 57 
To map the expression of FAPα expressing cells in the RA synovium we 58 
used mass cytometry (CyTOF), together with a combination of  podoplanin 59 
(PDPN) and THY1 (CD90) to discriminate sub-lining layer (SL, THY1+) from 60 
lining layer (LL, THY1-) fibroblasts, as in previous studies4,5,11. FAPα co-61 
localized with PDPN in both the LL and SL cells (Fig 1d). A small subset of 62 
pericytes (defined as CD45- PDPN- and THY1+) also expressed FAPα. 63 
These findings were confirmed by confocal analysis in RA synovial tissue 64 
(Fig 1e).    65 
 66 
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To determine the role of FAPα+ SFs in arthritis, we used serum transfer 67 
induced arthritis (STIA)12 in a transgenic FAPα luciferase-DTR reporter 68 
mouse13. FAPα expression (bioluminescence) increased during the course 69 
of arthritis (Fig 1f,g) and correlated with the severity of ankle joint swelling 70 
(Fig 1h). Synovial expression of FAPα was either low or undetectable 71 
under resting conditions (extended data 1a) but increased in SM and focal 72 
areas of pannus tissue invading cartilage and bone during inflammation 73 
(Fig 1i,j and extended data 1a). FAPα expression was restricted to 74 
mesenchymal cells (CD45-) (extended data 1b-f) and the number of FAPα+ 75 
fibroblasts increased during inflammation returning to baseline levels with 76 
resolution of inflammation (Fig 1k and extended data 1c,d), confirming 77 
that FAPα is a biomarker of tissue inflammation (Fig 1f-k, extended data 78 
1a,c,d).  79 
 80 
In the murine synovium, THY1 expression also distinguished SL from LL 81 
fibroblasts, with FAPα expressed in both cellular compartments (extended 82 
data 1e,f,g). Pdpn, Fap and Thy1 mRNA showed a significantly higher 83 
induction in the inflamed SM (Fig 1l) and expression positively correlated 84 
with joint swelling (Fig 1m). A significant increase in the proliferation of both 85 
THY1- FAPα+ (LL) and THY1+ FAPα+ (SL) cells was observed during 86 
inflammation, with very little change in the number of FAPα expressing 87 
pericytes (Fig 1n). The severity of joint inflammation positively correlated 88 
with the total number of FAPα+ THY1+ expressing cells but not FAPα+ 89 
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THY1- cells (extended data 1h). The extent of cartilage damage did 90 
however correlate with the number of FAPα+ THY1- cells (extended data 91 
1i), whereas the severity of bone erosion positively correlated with the 92 
number of FAPα+ THY1+ cells and not FAPα+ THY1- cells (extended data 93 
1j). Collectively these data suggest the expansion of a potentially 94 
pathogenic population of SFs is marked by expression of PDPN, FAPα and 95 
THY1. 96 
 97 
To determine the functional role of FAPα+ fibroblasts in vivo we selectively 98 
deleted FAPα+ cells during arthritis (extended data 1k-m). Deletion led to a 99 
significant reduction in the cellularity of the SM (extended data 1n-p), 100 
attenuated synovial inflammation and accelerated resolution in both the 101 
resolving (Fig 2a) and persistent models of STIA (Fig 2b), with the same 102 
effect observed regardless of the stage of arthritis at time of deletion 103 
(extended data 2a,b). However, deletion prior to induction of arthritis, had 104 
no effect on joint thickness (extended data 2c), an observation consistent 105 
with the low numbers of  FAPα+ cells in the SM under resting conditions 106 
(extended data 1a,c). Deletion of FAPα+ cells reduced structural joint 107 
damage (cartilage and bone damage), inflammatory bone re-modelling, 108 
pannus formation  (Fig 2c,d and extended data 2d-f), osteoclast numbers 109 
(Fig 2d, extended data 2g,h), and reduced expression of osteoclast and 110 
osteoblast bone markers in whole joint tissue (extended data 2i).  111 
 112 
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FAPα+ cell deletion led to reduced leucocyte infiltration (Fig 2e), negatively 113 
correlated with the severity of joint inflammation (Fig 2f) and was 114 
associated with a reduction in the number of both LL and SL fibroblasts, 115 
with no significant change in pericyte numbers (Fig 2g). Circulating blood 116 
monocyte number and phenotype were unchanged (extended data 3a), 117 
excluding any potential indirect effects of myelosuppression. Accompanying 118 
these changes was a marked reduction in the number of synovial 119 
leucocytes, specifically neutrophils, macrophages, CD11b+ dendritic cells 120 
and monocytes, but not eosinophils (extended data 3b for gating strategy, 121 
Fig 2h for resolving STIA model data and extended data 3c, for persistent 122 
model), as well as a reduction in the percentage of MHC Class II 123 
expressing macrophages (persistent model: extended data 3c and 124 
resolving model: extended data 3e). There were very few remaining 125 
macrophages in the SM following FAPα+ cell deletion (extended data 3d) 126 
and those remaining had a more anti-inflammatory phenotype (extended 127 
data 3f). These cellular changes in the synovium were accompanied by a 128 
marked reduction in pro-inflammatory chemokines, cytokines, RANKL and 129 
MMPs (Fig 2i), demonstrating that synovial FAPα+ cells are a significant 130 
source of these proteins. 131 
 132 
To exclude an indirect effect of systemic deletion of FAPα+ cells, we 133 
delivered DTx locally to the joint. This resulted in cell deletion in the SM but 134 
not in draining or distant lymph nodes (extended data 3g) and did not 135 
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result in systemic cachexia (extended data 3h), reported previously after 136 
systemic FAPα+ cell deletion13. Local deletion had the same effect on joint 137 
inflammation and bone damage with no effect observed in non-injected 138 
joints or following administration of DTx in non-arthritic mice (extended 139 
data 3i-k). 140 
 141 
We next explored whether both THY1- FAPα+ (LL) and THY1+ FAPα+ (SL) 142 
fibroblast populations contribute equally to inflammation and bone damage. 143 
We first performed single cell RNA sequencing of CD45- non-144 
haematopoietic cells from inflamed mouse synovium. After assigning 145 
identities to all cell clusters (Fig 3a, extended data 4a-d, 5, 6, 146 
supplementary table 1), targeted re-analysis of the fibroblast populations, 147 
based on expression of known fibroblast markers, revealed the existence of 148 
five distinct subgroups (Fig 3b, extended data 6 and 7a-d, 149 
supplementary table 1). Gene ontology (GO) analysis of significant cluster 150 
marker genes suggested a diversification of function between the subsets. 151 
F1 fibroblast marker genes were over-represented in categories related to 152 
bone, cartilage and extra-cellular matrix formation. F2 cells were strongly 153 
characterised by expression of inflammatory genes including those involved 154 
in “cytokine production” and “regulation of leukocyte chemotaxis”. 155 
Meanwhile, F3 fibroblasts showed an enrichment for genes involved in the 156 
“complement activation” and “vasculogenesis” biological processes. F4 157 
fibroblasts expressed genes characteristic of an actively cell cycling 158 
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population. Finally, F5 fibroblasts displayed a phenotype that included a 159 
distinctive over-representation of genes associated with “acid secretion” 160 
and “hydrogen transport” (Fig 3c, supplementary table 2).  161 
 162 
Examination of the top cluster marker genes allowed us to easily 163 
differentiate these five subsets at the mRNA expression level (Fig 3d). 164 
While Pdpn and Fap were expressed by all of the fibroblast subsets, Thy1 165 
was expressed selectively by F1-F4 fibroblasts but not F5 fibroblasts (Fig 166 
3d, extended data 6), suggesting that we could use THY1 as a marker to 167 
discriminate the LL F5 subset from the four SL clusters (F1-F4). We also 168 
examined the expression of other known fibroblast markers across the 169 
subsets as well as the specific expression of selected chemokines 170 
(extended data 7a,c).  171 
  172 
We next examined the potential development relationship between the 173 
different fibroblast subsets using a diffusion map (Fig 3e). Application of the 174 
pseudotime algorithm Slingshot14, identified two single-branch trajectories 175 
comprising of F1-F2-F3-F4 and F1-F2-F5. Existence of the F1-F2-F5 176 
trajectory is consistent with the diffusion map topology and analysis of 177 
genes differentially expressed along this trajectory (extended data 8a) 178 
showed that cells of cluster F2 have overlapping profiles with those of F1 179 
and F5. 180 
 181 
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To investigate the existence of homologous fibroblast subsets in human 182 
arthritis, we selectively re-analysed data from RA patient synovial 183 
biopsies15. This analysis identified five distinct sub-populations (extended 184 
data 8b-e). Correlation of orthologous (one-to-one) cluster markers from 185 
the human and mouse datasets identified three homologous populations of 186 
fibroblasts (Fig 3f) that share distinctive gene expression profiles (Fig 3g). 187 
The homologous clusters comprised of (i) LL fibroblasts (Mm STIA F5 – Hs 188 
RA F4), (ii) Cd34+ve SL fibroblasts (Mm STIA F3 – Hs RA F5) and (iii) 189 
Col11a1+ve SL fibroblasts (Mm STIA F1 – Hs RA F2).  190 
 191 
To confirm the validity of using PDPN, THY1 and FAPα as a cassette of cell 192 
surface markers to discriminate LL and SL fibroblasts, we performed ultra-193 
low input RNA sequencing on  purified PDPN+, FAPα+/- and THY1+/- cell 194 
populations (extended data 9a-d, supplementary tables 3-6). Principal 195 
component analysis of transcriptional differences confirmed that the 196 
subsets defined by expression of THY1 represented transcriptionally 197 
distinct populations with the most obvious separation between THY1+ 198 
versus THY1- populations regardless of FAPα expression (extended data 199 
9b). The THY1+ cell population showed expression of many chemokines 200 
and cytokines and expressed F1-F4 subset specific genes (extended data 201 
9c,d). In contrast, THY1- cell gene expression was consistent with F5 202 
fibroblasts associated genes such as Prg4, Clic5 and Tspan15 as well as 203 
genes associated with cartilage and bone erosion. Therefore the greatest 204 
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determinant of the transcriptional profile of SFs appeared to be their 205 
anatomical location in the SM (as defined by THY1 expression).  206 
 207 
As predicted from the single cell transcriptome analysis, FAPα+ THY1+ 208 
subsets had an immune effector profile with higher expression of 209 
chemokines as well as cytokines including: Il6, Lif, Il33 and Il34. In contrast, 210 
FAPα+ THY1- expressing subsets expressed higher levels of Ccl9 and 211 
TNFSF11 both potent inducers of osteoclast activity, as well as Mmp3, 212 
Mmp9 and Mmp13; matrix metalloproteinases involved in cartilage 213 
degradation (extended data 9d). These findings were validated, where 214 
possible for protein expression (Fig 4a). FAPα+ THY1- cells also expressed 215 
RANKL on their surface, secreted higher levels of RANKL, exhibited a 216 
significantly increased RANKL/OPG ratio (Fig 4b,c) and stimulated 217 
osteoclast differentiation/activation in vitro, leading to significantly more 218 
resorption of hydroxyapatite matrix in vitro (Fig 4d). Taken together these 219 
results support the concept that THY1- and THY1+ cells might perform 220 
distinct non-overlapping functions in vivo.  221 
 222 
To directly test this hypothesis we injected PDPN+ FAPα+ THY1- or PDPN+ 223 
FAPα+ THY1+ cells into the inflamed ankle joint of mice during STIA. 224 
Injection of PDPN+ FAPα+ THY1+ cells resulted in more severe and 225 
sustained joint swelling (Fig 4e), with higher levels of leucocyte infiltration 226 
(Fig 4f) but with little effect on bone and cartilage destruction (Fig 4g,h). In 227 
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contrast, the injection of PDPN+ FAPα+ THY1- cells had no effect on the 228 
severity or temporal dynamics of joint inflammation (Fig 4e,f), but did result 229 
in increased osteoclast activity and increased structural joint damage (Fig 230 
4g,h). The same effects were observed following the injection of each cell 231 
population into an inflamed ankle joint of mice with collagen induced 232 
arthritis (CIA) (extended data 10a,b). In this case, injection of PDPN+ 233 
FAPα+ THY1+ also resulted in increased effector CD4+ T cells, reduced 234 
Foxp3+ Tregs, and a global increase in neutrophil and macrophage cell 235 
infiltration (extended data 10c).  236 
 237 
Following joint injection, cells engrafted into the SM, remaining largely at 238 
the site of injection and were detectable up to 14 days after injection 239 
(extended data 10d). They maintained their original cell phenotype with 240 
regards to THY1 expression (extended data 10e) but did not preferentially 241 
localise to any specific anatomical compartment of the SM. No significant 242 
difference in the level of engraftment or viability between injected cell 243 
populations was observed (extended data 10f). Collectively, these data 244 
suggest that in pathological conditions PDPN+ FAPα+ THY1+ expressing 245 
cells assume an immune effector role capable of sustaining inflammation 246 
through the production of a distinct repertoire of chemokines and cytokines, 247 
whereas PDPN+ FAPα+ THY1- cells are bone effector cells that mediate 248 
joint damage.  249 
 250 
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In support of this conclusion, and as validation of the relevance of our 251 
findings to human disease, we identified an expanded population of PDPN+ 252 
FAPα+ THY1+ immune effector fibroblasts in the synovia of patients with 253 
RA, in whom joints are persistently inflamed, compared to patients with 254 
osteoarthritis (OA), a disease characterised predominately by cartilage  255 
damage rather than inflammation (Fig 4i). The expansion of PDPN+ THY1+ 256 
FAPα+ cells positively correlated with markers of systemic and tissue 257 
inflammation (Fig 4j). 258 
 259 
In summary, we have identified and described the pathological significance 260 
of fibroblast heterogeneity in RA, an IMID in which inflammation and 261 
damage play key pathogenic roles. We describe discrete, anatomically 262 
distinct subsets of fibroblasts with non-overlapping effector cell functions 263 
including joint and cartilage damage (production of MMPs and induction of 264 
osteoclastogenesis) and immuno-inflammatory regulation (production of 265 
inflammatory cytokines and chemokines). These findings provide the 266 
unpinning justification for the development of therapies that selectively 267 
target deletion or replacement of different mesenchymal subpopulations in 268 
a wide range of diseases. 269 
 270 
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 365 
FIGURE LEGENDS: 366 
Fig. 1: FAPα+ SFs accumulate in the arthritic joint. (a) Representative 367 
images of FAPα expression in synovial tissue and (b) quantification, with 368 
(c) matched Fap transcript expression in SFs expanded in vitro (n=8 369 
control, 9 resolving and 11 RA, patient samples). (d) CyToF viSNE plots of 370 
CD45- cells and (e) confocal microscopy of RA synovium (both 371 
representative of n=8, RA patient samples). (f) Serial measurements of 372 
bioluminescence signal in FAPα-luciferase mice and (g) quantification 373 
during STIA (n=8 mice). (h) Spearman’s correlation between 374 
bioluminescence and joint thickness (n=30 mice). (i) Representative image 375 
of FAPα (red) expression in hind limb joints of day 9 STIA mice, arrows 376 
indicate FAPα expression and (j) quantification (n=10 mice per group). (k) 377 
Fap transcript expression in sort purified synovial CD45- CD31- cells during 378 
STIA (n=8 mice, per time point). (l) Fold change in mRNA expression of 379 
stromal markers in the synovia of day 9 STIA compared to control mice 380 
(n=8 mice). (m) Spearman’s correlation between combined expression of 381 
Pdpn, Thy1 and Fap, and ankle joint thickness (n=44 mice). (n) Change in 382 
absolute numbers and percentage of Ki67+ and BrdU+ cells during STIA 383 
(n=6 mice). Statistics: Kruskal-Wallis with Dunn’s post-hoc, b,c, 1-way 384 
ANOVA with Dunnett’s post hoc, compared to day 0, g or day 3 k, two-385 
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tailed Mann-Whitney test j, 2-way ANOVA with Tukey’s post hoc, l,n. Data 386 
represented as Mean+S.D., except g,k,l, which are shown as box plots 387 
(centre line, median; box limits, upper and lower quartiles; whiskers, 388 
maximum and minimum values).  389 
 390 
Fig. 2: Deletion of FAPα expressing cells attenuates synovial 391 
inflammation. (a) Joint inflammation in deleted (STIA DTR+, n=13) versus 392 
non-deleted (STIA DTR-, n=9) STIA mice compared to non-arthritic deleted 393 
(DTR+, n=6) and non-deleted (DTR-, n=6) mice, with AUC analysis. (b) 394 
Effect of sustained FAPα cell deletion on joint inflammation in persistent 395 
STIA (STIA, DTR+/DTR- n=8 mice, and non-arthritic DTR+/DTR-, n=4 mice), 396 
with AUC analysis. (c) Representative micro-CT and histological images of 397 
day 28 persistent STIA mice with (d) quantification of micro-CT data, 398 
osteoclast number and histomorphometric analysis of bone erosion, pannus 399 
formation and cartilage damage, arrows indicate areas of interest (all: n=16 400 
mice per group). (e) Representative histology at day 9 STIA and 401 
quantification (n=14 mice per group), arrow shows leucocyte infiltration and 402 
SM=synovial membrane. (f) Spearman’s correlation between the 403 
percentage of FAPα cell deletion achieved at day 9 and change in ankle 404 
joint thickness (n=45 mice). (g) Quantification of the number of fibroblasts 405 
and pericytes (n=8 mice) and (h) leucocyte subsets (n=13 mice) in day 9 406 
STIA synovia analysed by flow cytometry. (i) Expression of selected mRNA 407 
transcripts and proteins (by luminex analysis following stimulation ex vivo 408 
Croft et al   Page 18 of 47 
 
with TNFα) in the synovia of DTR- and DTR+ day 9 STIA mice following DTx 409 
treatment, expressed as fold change in expression compared to non-410 
arthritic mice (n=8 mice per group for mRNA and n=6 mice per group for 411 
protein analysis). Statistics: 1-way ANOVA with Dunnett’s multiple 412 
comparison test a,b, two-tailed paired Student’s t-test (d,e), 2-way ANOVA 413 
with Tukey’s multiple comparison test (f,g). Data represented as 414 
Mean+S.D., except AUC analysis (in a and b) and f,g, which are shown as 415 
box plots (centre line, median; box limits, upper and lower quartiles; 416 
whiskers, maximum and minimum values).  417 
 418 
Fig. 3. Single-cell RNA-sequencing reveals distinct fibroblast subsets. 419 
(a) t-SNE projection showing 2814 non-hematopoietic (CD45- CD31- cells) 420 
stromal cells from the inflamed synovium of day 9 STIA mice (n=3 biological 421 
replicates). Cells are coloured according to major cell type based on 422 
expression of known marker genes (Extended data 4 and 5). (b) 423 
Unsupervised graph-based clustering16 of fibroblasts (n=1725 cells) reveals 424 
five subsets (F1-F5) in the inflamed STIA joints. For (c) and (d) conserved 425 
cluster marker genes were first identified as those with a maximum BH 426 
adjusted p value < 0.1 in separate tests of cells from each of the n=3 427 
biological replicates (two-sided Wilcoxon tests, supplementary table 1). (c) 428 
Over-representation analysis of Gene Ontology (GO) categories suggests 429 
different functions for the five STIA fibroblast subsets. Significant 430 
enrichments amongst cluster markers (BH adjusted p < 0.05, one-sided 431 
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Fisher’s exact tests, supplementary table 2) are shown in colour. (d) 432 
Expression of marker genes (x axes) in the identified STIA fibroblast 433 
clusters (y axes). The first panels show expression of known pan-fibroblast 434 
markers. The remaining sets of panels show examples of identified 435 
conserved makers genes for each fibroblast cluster F1-F5. (e) Embedding 436 
of the STIA fibroblasts in the first three components of a diffusion reveals 437 
possible relationships between the clusters. (f) Comparison of the 438 
fibroblasts clusters from the mouse (Mm) STIA model with those from 439 
human (Hs) RA patients15. Hierarchical clustering of orthologous (one-to-440 
one) cluster markers identified three sets of homologous subpopulations. 441 
(g) Selected markers commonly expressed between homologous human 442 
and mouse clusters. 443 
 444 
Fig. 4: Fibroblast subsets are responsible for different aspects of 445 
disease pathology. (a) Luminex analysis of stimulated FAPα+ THY1- and 446 
FAPα+ THY1+ cells isolated from day 9 STIA synovia, (b) secretion of 447 
RANKL and OPG (n=6 mice per group) and (c) quantification of the 448 
synovial RANKL+ THY1-/+ cells by flow cytometry (numbers=percentage of 449 
cells, n=8 mice per group). (d) Effect of FAPα+ THY1- and FAPα+ THY1+ 450 
cells on the number of osteoclasts, N. Oc, (n=4 mice per group) and matrix 451 
degradation in vitro (n=8 mice per group). (e) Effect of IA injection of PDPN+ 452 
FAPα+ THY1- or PDPN+ FAPα+ THY1+ cells into the ankle joints of day 3 453 
STIA mice compared to contra-lateral sham injected joints, with AUC 454 
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analysis (n=8 mice per group). (f) Flow cytometric analysis of absolute 455 
number of leucocyte subsets isolated from the digested synovia of injected 456 
joints at day 12 (n=8 mice per group). (g) Representative images at day 12 457 
and (h) quantification of micro-CT data, and histomorphometric analysis of 458 
osteoclast number, cartilage damage, bone erosion and synovial pannus 459 
(n=16 mice per group). (i) Mass cytometry (CyToF) analysis of PDPN+ 460 
FAPα+ and THY1+/- cells in synovium of patients with OA and RA (n=15 OA, 461 
n=8 RA patient samples). (j) Spearman’s correlation between THY1+ FAPα+ 462 
cells in RA and serum ESR level and synovial Krenn score (n=8 RA patient 463 
samples). Statistics: two-tailed paired Student’s t-test (a-d,l), 1-way ANOVA 464 
with Dunnett’s post hoc test compared to sham injected (e,f), two-tailed 465 
paired Student’s t-test (AUC, e and f,h). Data represented as Mean+S.D., 466 
except c,d,f,l and AUC analysis in e, which are shown as box plots (centre 467 
line, median; box limits, upper and lower quartiles; whiskers, maximum and 468 




Human subjects research 473 
Human subjects research was performed according to the Institutional 474 
Review Boards at Partners HealthCare, Hospital for Special Surgery and 475 
the West Midlands and Black Country Research Ethics Committee via 476 
approved protocols with appropriate informed consent. The study was 477 
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compliant with all relevant ethical regulations. Synovial tissues and clinical 478 
outcome data of patients included in the early arthritis patient cohort in 479 
Birmingham (BEACON) were used in this study10. All patients were naïve to 480 
treatment with disease modifying anti-rheumatic drugs (DMARDs) and 481 
corticosteroids at inclusion. Control synovial tissue was obtained from 482 
uninflamed joints of patients with joint pain but normal imaging studies 483 
undergoing exploratory arthroscopy. Samples from patients with 484 
osteoarthritis were obtained from arthroplasty procedures and tissue from 485 
patients with RA obtained by ultrasound guided synovial biopsy as 486 
previously described10,15.  487 
 488 
Human synovial tissue processing, histological analysis and 489 
immunofluorescence staining 490 
Synovial tissue samples were frozen in Tissue-Tek OCT medium (Miles, 491 
Elkhart, IN) or formalin fixed and paraffin embedded (FFPE). 492 
For immunohistochemistry, antigen retrieval was performed at pH 9 on 493 
FFPE sections using Tris-EDTA, 0.05% Tween 20 (10mM Tris Base, 1mM 494 
EDTA Solution, 0.05% Tween 20). Sections were stained using anti-FAPα 495 
(R&D) and anti-goat Horseradish peroxidase (HRP) (Dako). HRP staining 496 
was developed using the ImmPACT DAB Peroxidase HRP Substrate 497 
(Vector Labs). Images were acquired using the Zeiss Axio Scan and 498 
analysed with Zen lite 2012 software (Zeiss). Number of pixels was 499 
quantified and divided by a manually defined tissue area and the average 500 
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number of pixels per unit area (pixel/UA) was calculated. 501 
For immunofluorescence, acetone fixed frozen sections were incubated 502 
with anti-FAPα (F11-24, eBioscience), anti-PDPN (NZ-1.3, eBioscience) 503 
and anti-THY1 (Thy-1A1, R&D). These were detected with goat anti-mouse 504 
IgG1 FITC, anti-mouse IgG2a TRITC and anti-mouse IgG2b Cy5 (all 505 
Southern Biotech). To increase signal from FITC-channel, goat anti-FITC 506 
Alexa-488 antibody (Invitrogen) was used. Images were acquired using a 507 
Zeiss LSM 510 confocal microscope and ZEN pro 2011 imaging software.  508 
 509 
Human fibroblast cell culture 510 
Human fibroblasts were isolated as described18 and cultured in Dulbecco’s 511 
modified Eagle’s medium (DMEM) (Sigma-Aldrich) with 2% fetal bovine 512 
serum (FBS; Gemini), 2 mM L-glutamine, antibiotics (penicillin and 513 
streptomycin), and essential and non-essential amino acids (Life 514 
Technologies). Fibroblast lines at passage 3 or 4 were used for in vitro 515 
experiments. 516 
 517 
Enzymatic digestion of human synovial tissue 518 
Synovial tissue samples were disaggregated into single cell suspension as 519 
previously described19. Synovial tissue fragments were separated using 520 
Liberase TL (100μg/mL; Sigma-Aldrich) and DNase I (100μg/ml; Roche) in 521 
RPMI in a 37oC water bath for 30min. Single cell suspensions were 522 
assessed for cell quantity and cell viability.  523 
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 524 
Mass cytometry on human synovial cells 525 
Cryopreserved disaggregated human synovial cells were thawed into RPMI 526 
+ 10% FBS (HyClone). Viability was assessed and cells were stained with 527 
primary antibody cocktails at 1:100 dilution (CD45, metal 89Y, clone HI30; 528 
PDPN, metal 156Gd, clone NC-08; FAP, metal 147Sm, Poly; THY1, metal 529 
162Dy, clone 5E 10). All antibodies were obtained from the Longwood 530 
Medical Area CyTOF Antibody Resource Core. Cells were fixed and 531 
permeabilized using the eBioscience Transcription Factor Fix/Perm Buffer 532 
followed by staining for intracellular markers. Cells were re-fixed in formalin 533 
(Sigma-Aldrich), washed with Milli-Q water, and analyzed on a Helios 534 
(Fluidigm). Mass cytometry data were normalized using EQ™ Four Element 535 
Calibration Beads (Fluidigm) viSNE analyses were performed on cytometry 536 
data, using the Barnes-Hut SNE implementation on Cytobank 537 
(www.cytobank.org). All biaxial gating was performed using FlowJo 10.0.7.  538 
 539 
Histological analysis of human synovial biopsy tissue  540 
H&E stained sections of synovial biopsy tissue samples were scored for the 541 
severity of inflammatory infiltrate using the inflammatory component of the 542 
Krenn synovitis score20. Inflammatory infiltrates were graded from 0 to 3 543 
(0=no inflammatory infiltrate, 1=few mostly perivascular situated 544 
lymphocytes or plasma cells, 2=numerous lymphocytes or plasma cells 545 
sometimes forming follicle-like aggregates, and 3=dense band-like 546 
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inflammatory infiltrate or numerous large follicle-like aggregates). Sections 547 
were scored by two blind individuals and then provided consensus. 548 
 549 
Mice 550 
All animal experiments were approved by the U.K. Home Office and 551 
conducted in accordance with the U.K.’s Animals (Scientific Procedures) 552 
Act 1986 and the U.K. Home Office Code of Practice. The project and 553 
experimental protocols were approved by the University of Birmingham 554 
Animal Ethics Review Committee who provided ethical oversight of the 555 
study. 556 
C57BL/6 mice were purchased from Charles River and DBA/1 mice from 557 
Envigo. FAPα-DTR transgenic (Tg) embryos were a gift from Prof Douglas 558 
Fearon, generated as previously described13. ROSAmT/mG mice were 559 
purchased from Jackson laboratory and bred in the unit. All mice were 560 
housed at a barrier and specific pathogen-free facility at the Biomedical 561 
Services Unit, University of Birmingham. All mice used in experimental 562 
studies were male or females aged 8-10 weeks. Single animals were 563 
considered as experimental units.  564 
 565 
In vivo imaging 566 
FAPα-DTR mice were injected intra-peritoneally (i.p.) with 150µg/g body 567 
weight D-luciferin (PerkinElmer) and serially imaged using IVIS (Xenogen). 568 
The count data was normalised and expressed as radiance units of 569 
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photons/second/cm2/steradian (normalised bioluminescence) using Living 570 
Image software, version 4.7 (PerkinElmer) and presented as percentage 571 
change from baseline signal. 572 
 573 
Diphtheria toxin mediated deletion of FAPα expressing cells 574 
Diphtheria Toxin (DTx) (List Biological Laboratories) was administered by 575 
i.p. injection FAPα-DTR mice (25ng/g), twice a day, both in prophylactic (at 576 
day -7 and -5 pre STIA) and in therapeutic regimes (at days 3 and 5 or at 577 
days 5 and 7 or at days 10 and 12 post STIA). For the persistent 578 
inflammatory arthritis model, DTx injections (25ng/g) were performed on 579 
day 3 and day 5 initially and then once a week. For local deletion of FAPα+ 580 
cells, DTx (5ng/g) was administrated by intra-articular (IA) injection into talo-581 
tibial joint at day 4 and 6 post STIA. Sterile water for injections was used as 582 
vehicle control. 583 
 584 
Mouse models of inflammatory arthritis 585 
STIA was induced by intra-venous (i.v) injection of 100μl arthritogenic 586 
serum from KRN mice (K/BxN)12. Ankle or wrist joint thickness was 587 
monitored using callipers and reported as the change from baseline. In the 588 
persistent model of arthritis, mice were administered 100μl arthritogenic 589 
serum i.v. at day 0 and then 50μl once a week. Severity of joint swelling 590 
was quantified using the area under the curve (AUC) analysis of serial 591 
measurements.  592 
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For BrdU incorporation, mice were injected with 100μl of 10mg/ml BrdU in 593 
PBS and then kept on BrdU-containing drinking water (0.8mg/ml).  594 
For collagen induced arthritis male DBA/1 mice were immunised with 100 or 595 
200µg of rat CII emulsified 1:1 in complete Freund's adjuvant (CFA; Difco, 596 
containing Mycobacterium butyricum, 0.5 mg/ml) or Freund's incomplete 597 
adjuvant (IFA) containing Mycobacterium tuberculosis H37Ra (Difco; 3.33 598 
mg/ml). Mice were boosted 3 weeks later with 100µg CII in IFA.  599 
 600 
Mouse synovial tissue digestion 601 
Bones with intact joints were dissected and transferred into RPMI-1640 602 
(+2% FCS) containing 0.1g/ml Collagenase D (Roche), 0.01g/ml of DNase I 603 
(Sigma-Aldrich). Samples were incubated at 37°C, 40min, followed by 604 
incubation with medium containing 0.1g/ml Collagenase Dispase (Roche) 605 
and 0.01g/ml DNase I at 37°C for 20min.  606 
 607 
Flow cytometry and cell sorting 608 
Cells were stained at 4°C and dead cells excluded using Zombie 609 
Yellow staining (BioLegend). Peripheral blood was harvested by cardiac 610 
puncture into EDTA tubes, centrifuged and red cell lysis performed prior to 611 
staining. Antibodies used were anti-CD45 (30-F11), anti-THY1 (53-2.1), 612 
anti-podoplanin (8.1.1), Streptavidin APC (17-4317-82), anti-CD31 (390), 613 
anti-CD11b (M1/70), anti-SiglecF (1RNM44N), anti-CD11c (N418), anti-614 
ITGA7 (334908), from eBioscience; anti-Ly-6G (1A8), anti-CD64 (X54-615 
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5/7.1), anti-F4/80 (BM8), anti-RANKL (IK22/5), anti-Ki67 (11F6), anti-616 
CD140b (APB5), anti-CD146 (ME-9F1), anti-CD115 (AFS98), anti-CD43 617 
(S11), anti-MHC Class II (39-10-8) and anti-Ly-6C (HK1.4), from 618 
BioLegend; anti-FAPα (R&D), mouse anti-goat/sheep IgG biotin (GT-34, 619 
Sigma Aldrich); and anti-BrdU (3D4, BD Biosciences). BrdU staining was 620 
performed according to manufacturer’s instructions using a BrdU Flow Kit 621 
(BD Pharmigen™). CountBright™ absolute counting beads (Thermofisher) 622 
were used for analysis of cell numbers by flow cytometry, according to 623 
manufacturer’s guidelines. Samples were acquired using a BD LSR 624 
Fortessa and analyzed by FlowJo, version 10.5.3. Cell sorting was 625 
performed immediately after staining using a MoFlo Astrios EQ machine 626 
(Beckman Coulter). For post sort populations purity was determined by re-627 
analysis for the target population based on cell surface markers 628 
immediately post sorting. Purity was >99% for each target population. 629 
 630 
Generation and analysis of droplet-based single cell RNA sequencing 631 
data 632 
Following sorting, CD45- live synovial cells isolated from hind limbs 633 
of day 9 STIA inflamed mouse joints (n=3 biological replicate samples, each 634 
comprised of cells isolated from the joints of three animals) were captured 635 
with the 10X Genomics Chromium system. Sequencing libraries were 636 
generated using the 10x Genomics Single Cell 3’ Solution (version 2) kit 637 
and subjected to Illumina sequencing (HiSeq 4000, read 2 sequenced to 638 
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75bp). Alignment, quantitation and aggregation of sample count matrices 639 
was performed using the 10x Genomics Cell Ranger pipeline (version 2.1.0) 640 
and mouse reference sequences (version 2.1.0), retaining a median of 641 
59.9k reads/cell (mapped-read depth normalization applied). To circumvent 642 
known index-hopping issues with the HiSeq 4000 platform21 cell barcodes 643 
common to more than one sample were removed from the aggregated 644 
count matrix. The UMI count matrix was randomly down-sampled to a 645 
common median number of per-cell counts between the samples. 646 
Downstream analysis was performed using the Seurat R package (version 647 
2.3.0)16 as follows. Cells with greater than 5% mitochondrial reads or fewer 648 
than 500 genes were excluded from the analysis. Cells were down-sampled 649 
to a common number: for the full analysis we retained n=938 cells per 650 
replicate, while n=575 cells were retained per replicate for re-analysis of the 651 
fibroblasts. Per-cell counts were normalised, scaled and the effects of total 652 
UMI counts and percentage of mitochondrial counts regressed out. For the 653 
fibroblast re-analysis, the difference between G2M and S phase was also 654 
regressed out based on the expression of known cell cycle marker genes22. 655 
In both cases, we retained the first 30 principle components for tSNE 656 
projection and clustering analysis (original Louvain algorithm, resolution set 657 
to 0.6 for the full analysis and to 0.4 for the  fibroblast reanalysis). 658 
Conserved cluster markers were identified as the intersection of those that 659 
were significant in separate tests of the cells from the each replicate 660 
(Wilcoxon test, Benjamini Hochberg (BH) adjusted p values < 0.1). Only 661 
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genes found in 10% of cells (either within or outside the cluster of interest) 662 
and that showed a minimum log fold difference of 0.25 were tested for 663 
differential expression. Geneset over-representation analysis of cluster 664 
marker genes was performed using one-sided Fisher’s exact tests (as 665 
implemented in the “gsfisher” R package 666 
https://github.com/sansomlab/gsfisher) with Biological Process gene sets 667 
obtained from the Gene Ontology (GO) database23. For this analysis 668 
cluster-specific gene universes were defined as those genes expressed in 669 
at least 10% percent of cells (either within or outside the cluster of interest). 670 
The computational analyses were performed using the 671 
“pipeline_cellranger.py” and “pipeline_seurat.py” pipelines 672 
(https://www.github.com/sansomlab/tenx/).   673 
The diffusion map was generated using the “RunDiffusion” function in 674 
Seurat and the first 5 principal components. The pseudo-time tool 675 
Slingshot14 was used to determine possible lineages via fitting of minimum 676 
spanning trees to the clusters (30 diffusion components, start cluster “F1”). 677 
The clusters and cluster markers from the human dataset15 were obtained 678 
using the same workflow as described above (30 principal components and 679 
perplexity 100 for tSNE, resolution 0.6 for clustering). Only cells from RA 680 
patients and defined as fibroblasts by the authors were used in this 681 
analysis. 682 
 683 
Bulk cell population RNA sequencing 684 
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For these studies, cells were isolated from the synovia of digested hind limb 685 
joints of day 9 STIA mice and analyzed by flow cytometry. After gating for 686 
fibroblasts (gating strategy outlined in extended data 1b) cells were sort 687 
purified into selected populations according to the sorting strategy in 688 
extended data 9a (each n number represents a single mouse with cells 689 
isolated from the joints of both hind limbs) and collected in EDTA free 690 
buffer. RNA was extracted from freshly isolated cells using the PicoPure 691 
RNA isolation kit (Thermo Fisher Scientific) according to the manufacturer’s 692 
instructions. RNA quantity measured on the Qubit using the RNA HS kit 693 
(Invitrogen Q32852). Where samples were <5 ng/μl the Quantifluor RNA 694 
System was used (Promega E3310). cDNA synthesis was performed on 695 
isolated RNA using the SMART-Seq® v4 Ultra® Low Input RNA Kit for 696 
Sequencing (ClonTech 634890). Libraries were pooled and sequenced 697 
paired end 75 bases each end with the illumina NextSeq 500 system.  698 
 699 
The reads were mapped to the GRCm38 (Ensemble release 85) mouse 700 
genome using STAR alignment software version v2.5.2b24. Read counts per 701 
gene were produced by the same software. Sample normalization and 702 
differential expression analysis was performed using DESeq2 R 703 
Bioconductor package25. log2 values of read counts regularised by DESeq2 704 
were used in heatmaps in extended data  9. Gene set enrichment analysis 705 
was performed using GAGE R Bioconductor package26 with gene sets from 706 
the Gene Ontology database. 707 
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 708 
Luminex analysis 709 
Cells were stimulated with 1ng/ml recombinant mouse TNFα (Peprotech) ex 710 
vivo in culture medium for 1 hour. Fresh culture media was then applied 711 
and the subsequent supernatant was harvested after 12 hours and 712 
analysed using custom selected multiplex bead based assays (Luminex 713 
assay panel, R&D). 714 
 715 
Co-culture synovial fibroblasts-osteoclasts 716 
Sorted synovial fibroblasts were cultured in DMEM (+10% FCS, +1% GPS). 717 
Bone marrow was flushed out from tibiae and femurs of 8-10 weeks old 718 
C57BL/6 or GFP mice and osteoclast precursors were cultured 24 hours in 719 
alpha-MEM (+10% FCS, +1% Glutamine-Penicillin-Streptomycin (GPS)). 720 
Supernatant from the bone marrow culture was removed (containing 721 
haematopoietic osteoclast precursors), cells were seeded on top of the 722 
fibroblast culture in alpha-MEM (+10% FCS, +1% GPS, 1µM prostaglandin 723 
E2, 10ng/ml recombinant TNFα). Experiment was stopped after 5 to 6 days 724 
in co-culture. Wells were imaged using Zeiss Observer Z1 microscope 725 
(ZEISS). GFP positive osteoclasts were counted using Zen 2010 software. 726 
Resorption area in wells of Osteo Assay surface plates were analysed 727 
using Adobe Photoshop, version 19.1.6, and ImageJ, version 1.51 .  728 
 729 
Quantitative real time PCR  730 
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RNA was isolated from single cell suspensions using the PicoPure RNA 731 
isolation kit (Thermo Fisher Scientific) according to manufacturer’s 732 
instructions. For whole tissue analysis, frozen joints were pulverised in 733 
liquid nitrogen using a FreezerMill 6770 (Spex Sample Prep) and mRNA 734 
extracted using ReliaPrep™ RNA Tissue Miniprep System (Promega). 735 
cDNA synthesis was performed on all samples (500ng of RNA was 736 
transcribed) using iScript cDNA synthesis kit (Bio-Rad) on a Techne 312 737 
thermal cycler PCR machine.   738 
In order to amplify small amounts of cDNA without introducing amplification 739 
bias, TaqMan PreAmp Master Mix was used according to manufacturer’s 740 
instructions for flow sorted cell samples.  741 
Quantitative RT−qPCR was performed using Taqman assays and Taqman 742 
universal Mastermix (from Applied Biosystems) on a real-time PCR 743 
detection system (CFX96 Touch™ Real-Time PCR Detection System).  744 
Expression levels were normalized to an internal housekeeping gene 745 
(RPLP0 for human, β-actin for mouse) and calculated as 746 
2^−(CTHK−CTgene). TaqMan primer/probes (Applied Biosystems) used 747 
were Fap (human: Hs00990791_m1; mouse: Mm01329177_m1), Pdpn 748 
(Mm01348912_g1), Thy1 (Mm00493681_m1), CD34 (Mm00519283_m1), 749 
CD248 (Mm00547485_s1), Cdh11 (Mm00515466_m1), Pdgfra 750 
(MM00440701_m1), Vcam1 (Mm01320970_m1), Ccl7 (Mm00443113_m1), 751 
Csf2 (Mm01290062_m1), Ccl2 (Mm00441242_m1), Ccl5 752 
(Mm01302427_m1), Ccl8 (Mm01297183_m1), Ccl9 (Mm00441260_m1), 753 
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Ccl11 (Mm00441238_m1), Ccl19 (Mm00839967_g1), Cxcl1 754 
(Mm04207460_m1), Cxcl2 (Mm00436450_m1), Cxcl3 (Mm01701838_m1), 755 
Cxcl5 (Mm00436451_g1), Cxcl6 (Mm01302419_m1), Cxcl11 756 
(Mm00444662_m1), Cxcl12 (Mm00445553_m1), Cxcl13 757 
(Mm04214185_s1), Cxcl14 (Mm00444699_m1), il18 (Mm00434226_m1), 758 
Ptgs2 (Mm00478374_m1), Ptges (Mm00452105_m1), Prg4 759 
(Mm01284582_m1), Tnfsf11 (Mm00441906_m1), Mmp3 760 
(Mm00440295_m1), Mmp9 (Mm00442991_m1), Mmp13 761 
(Mm00439491_m1), Ctsk (Mm00484039_m1), Runx2 (Mm00501584_m1), 762 
Spp1 (Mm00436767_m1), Acp5 (Mm00475698_m1), Tnfrsf11a 763 
(Mm00437132_m1), Sost (Mm00470479_m1), BGLAP 764 
(Mm03413826_mH), Dmp1 (Mm01208363_m1), il6 (Mm00446190_m1), 765 
Tnf (Mm00443258_m1), il1b (Mm00434228_m1), il10 (Mm01288386_m1), 766 
inos (Mm00440502_m1) and Arg1 (Mm00475988_m1).  767 
 768 
Mouse tissue histology and immunofluorescence staining 769 
Mouse legs were fixed for 24 hours in 10% formalin solution (Sigma‐770 
Aldrich) and decalcified in 10% EDTA (pH 7.4). Samples were embedded in 771 
paraffin, sectioned and H&E staining was performed at the Royal 772 
Orthopaedic Hospital Pathology Laboratories according to standard 773 
protocol. Safranin O staining for cartilage was performed as previously 774 
described27. 775 
Antigen retrieval was performed on FFPE tissue sections; 0.05% trypsin-776 
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EDTA for PDPN, FAPα and Cathepsin K staining at 37°C, or citrate buffer 777 
pH6 (Dako) at 58°C for F4/80 staining. Sections were stained with primary 778 
antibodies: anti-PDPN (eBio8.1.1, eBioscience), anti-FAPα (R&D), anti-779 
F4/80 (BioRad), anti-CD146 (Abcam) or anti-Cathepsin K (Abcam). 780 
Secondary antibodies used were: biotin Goat anti-hamster IgG Antibody 781 
(BioLegend); biotin rabbit anti-sheep IgG (Vector Labs) biotin Goat anti-782 
rabbit IgG (H+L) (Life Technologies); biotin rabbit anti-Rat IgG (H+L) 783 
(Vector Labs), followed by Streptavidin HRP and DAB detection or alkaline 784 
phosphatase, Vector Labs. Tissue sections were imaged using the 785 
AxioScanZ.1 slide scanner and analysed using Zen lite 2012 software. 786 
Quantification by pixel counts was performed using Image J, version 1.51.  787 
For immunofluorescence, limbs were placed in a cryomold, embedded in 788 
OCT compound (both from Sakura Finetek) and stored at -80°C. Frozen 789 
sections were obtained with a tape transfer system CryoJane® (Leica 790 
Biosystems) and staining was performed on acetone-fixed sections with 791 
anti-PDPN (eBio8.1.1, Thermofisher), anti-FAPα (Abcam) and anti-THY1 792 
(53-2.1, Thermofisher). The following secondary antibodies were used: 793 
Streptavidin Alexa Fluor™ 555, goat anti-rabbit IgG (H+L) FITC, 794 
Fluorescein/Oregon Green Polyclonal antibody AlexaFluor™ 488, goat anti-795 
rat IgG (H+L) AlexaFluor™ 647, from Invitrogen; and biotin goat anti-796 
hamster IgG (BioLegend). Images were acquired using a Zeiss LSM780 797 
confocal microscope and ZEN pro 2011 imaging software.  798 
 799 
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Histomorphometry scoring 800 
Analysis and cell counting of H&E and Safranin O was performed on 801 
images from whole joint tissue sections as previously described28. 802 
Leucocyte infiltration was scored 0-3 (0=normal, 1= minimal infiltration, 803 
2=moderate infiltration, 3=marked infiltration). Osteoclasts were detected by 804 
both morphology and Cathepsin K staining. Scoring and measurements 805 
were performed by two independent blind assessors on a consistent region 806 
of the ankle joint and on three different cutting levels and expressed as a 807 
mean of these measurements.  808 
 809 
Adoptive transfer of fibroblasts  810 
500,000 live sort purified cells (from day 9 STIA) were injected into the 811 
inflamed talo-tibial joint at day 3 STIA recipient mice. Contralateral joint was 812 
injected with PBS. For CIA, cells were sort purified and injected into the 813 
ankle joint of DBA/1 mice with CIA at the first sign of arthritis, under the 814 
same experimental conditions described above.       815 
 816 
Tracking of adoptively transferred cells in vivo 817 
Cells were sort purified from digested synovia of day 9 STIA ROSAmTmG 818 
mice and injected as described above. Harvested tissue was mounted in 819 
OCT, frozen, sectioned and fixed in acetone. For flow cytometry, sort 820 
purified cells were labelled with a cell trace dye (Invitrogen) according to the 821 
manufacturer’s instructions prior to injection.  822 
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 823 
Micro-CT analysis 824 
Hind limbs were imaged using a Skyscan 1172 micro-CT scanner (Bruker) 825 
using settings and reconstruction algorithms using MeshLab, version 1.3.2, 826 
as previously described27. Micro-CT meshes were divided into 3 regions: 827 
heel (compromising the calcaneus, centrale, distal tarsals, tibulae and 828 
astagalus and distal tibia and fibula), metatarsals and phalanges (excluding 829 
the claws). Each region was scored for erosion (0=normal, 1=roughness, 830 
2=pitting, 3=full thickness holes) and the extent of the area affected 831 
(0=none, 1=a few small areas, 2=multiple small-medium areas, 3=multiple 832 
medium-large areas). The 2 scores were then multiplied together for each 833 
region. With the exception of local deletion and IA cell transfer studies, 834 
micro-CT scores from both the front and hind limb were combined as an 835 
average for each mouse.  836 
 837 
Statistical analysis 838 
Statistical analysis was performed as described in each section using Prism 839 
8 software. Unless otherwise stated data is presented as Mean+SD from 840 
data obtained from at least two independent experiments. Parametric and 841 
non-parametric analyses were used where appropriate based on testing for 842 
a normal distribution using the D’Agostino-Pearson Omnibus normality test. 843 
Differences were considered to be significant when p<0.05. Multiple testing 844 
corrections were applied where appropriate. 845 
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 846 
Data availability 847 
STIA single cell and bulk fibroblast RNA sequence data that support the 848 
findings of this study have been deposited in Gene Expression Omnibus 849 
(GEO) with the accession codes GSE129087 and GSE129451. Source 850 
data for figure(s) 1,2,4 and extended data 1,2,3 and 10 are provided with 851 
the paper. 852 
 853 
Code availability 854 
The source code repository of the computational pipeline for single cell data 855 
analysis and integration is located at 856 
https://www.github.com/sansomlab/tenx/. 857 
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 893 
Extended data legends 894 
Extended data 1: Mouse synovial FAPα expression. (a) Expression of 895 
PDPN and FAPα by immunohistochemistry in ankle joints (representative of 896 
n=8 mice). Flow cytometry of digested synovia: (b) gating strategy for SFs 897 
in digested synovia, (c) representative expression of PDPN and FAPα 898 
during STIA, (d) corresponding absolute numbers of FAPα+ cells (n=10 899 
mice per group), (e) plot of FAPα expression in THY1- (LL, blue) or THY1+ 900 
(SL, red) PDPN+ cells and PDPN- THY1+ pericytes (black) in day 9 STIA 901 
synovia (each plot representative of n=12 mice, numbers=percentage of 902 
cells). (f) Quantification of Fap transcript expression in sort purified cells 903 
(day 9 STIA synovia, n=12 mice). (g) Immunofluorescence staining for 904 
PDPN, FAPα and THY1 expression in day 9 STIA ankle joints 905 
(representative of n=12 mice). Spearman’s correlation analysis between the 906 
total (black), LL (blue) and SL (red) FAPα expressing cells quantified by 907 
flow cytometry and (h) the change in ankle joint thickness, (i) cartilage 908 
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destruction and (j) bone erosion (both by histology) (n=40 mice). (k) 909 
Representative bioluminescence of in vivo imaging of FAPα-DTR+ mice 910 
treated with DTx or Vehicle and (l) quantification of bioluminescence (n=8 911 
mice per group). (m) Quantification of synovial FAPα+ cells following 912 
administration of either DTx or Vehicle (n=8 mice per group). (n) 913 
Immunohistochemistry staining of FAPα (red) expression in ankle joints 914 
following DTx (representative of n=8 mice). (o) Total number of CD45- 915 
CD31- cells by flow cytometry in day 9 STIA synovia compared to non-916 
arthritic (control) mice following DTx (n=7 mice per group). (p) H&E staining 917 
and quantification of cellularity following DTx treatment. Arrow indicates 918 
SM. Data are expressed as the average number of cells per quantified per 919 
histological section (n=8 mice per group). Statistics: 2-way ANOVA with 920 
Tukey’s post hoc, (f,n,p). Data represented as Mean+S.D., except f,n which 921 
are shown as box plots (centre line, median; box limits, upper and lower 922 
quartiles; whiskers, maximum and minimum values.  923 
 924 
Extended data 2: Effects of FAPα cell deletion. Change in wrist and 925 
ankle joint thickness during STIA with AUC analysis following FAPα cell 926 
deletion at (a) days 5 and 7 and (b) days 10 and 12 or (c) prophylactically 927 
prior to the induction of STIA (n=8, mice per group). (d) Representative time 928 
course analysis of structural joint damage assessed by micro-CT following 929 
FAPα cell deletion at days 3 and 5 following induction of STIA, with (e) 930 
quantification of bone erosion and new bone formation (n=8 mice per 931 
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group), combined for front and hind paws. (f) Histological examination of 932 
ankle joint tissue sections at day 12 STIA with quantification of bone 933 
erosion, pannus formation and bone formation (all by H&E) and cartilage 934 
destruction (by Safranin O staining) (n=12 mice per group). (g) 935 
Representative images of cathepsin k immunohistochemical staining of 936 
osteoclasts (brown) in the ankle joints of day 12 STIA mice. (h) Number of 937 
osteoclasts (cathepsin k positive) per tissue section in DTR- versus DTR+ 938 
mice at day 12 STIA compared to non-arthritic control mice (n=12 mice per 939 
group). (i) Expression of bone turnover markers including osteoclast and 940 
osteoblast markers in whole paw tissue analysed by RT-PCR (n=8 mice per 941 
group, data are expressed as mean fold change in expression compared to 942 
expression in non-arthritic mice). Statistics: Mann Whitney test, a-c, 2-way 943 
ANOVA with Tukey’s post hoc, e, 1-way ANOVA with Tukey’s post hoc, f,h. 944 
Data represented as Mean+S.D., except AUC analysis in a-c which are 945 
shown as box plots (centre line, median; box limits, upper and lower 946 
quartiles; whiskers, maximum and minimum values.  947 
 948 
Extended data 3: Effect of FAPα cell deletion on leucocyte infiltration. 949 
(a) Flow cytometry plot of peripheral blood monocytes 950 
(numbers=percentage of positive cells) with quantification at day 9 STIA 951 
following DTx at day 3 and day 5 (n=6 mice per group). (b) Flow cytometry 952 
gating strategy for leucocyte populations in digested synovia. (c) Numbers 953 
of leucocytes and percentage of MHC Class II expressing F4/80 cells (M1) 954 
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in hind limb joints of day 28 persistent STIA mice analysed by flow 955 
cytometry (n=13 mice per group). (d) Representative immunohistochemical 956 
staining of macrophages (F4/80+, brown; nuclei blue) in the ankle joint 957 
tissue sections at day 12 STIA mice following DTx at day 3 and 5 958 
(representative of n=6 mice). (e) Percentage of F4/80+ macrophages 959 
staining positive for MHC Class II as detected by flow cytometry in day 12 960 
STIA digested synovia from DTR+/- mice following DTx at day 3 and 5 (n=13 961 
mice per group). (f) Expression of functional macrophage markers detected 962 
by RT-PCR in sort purified macrophages (CD45+ CD11b+ F4/80+) isolated 963 
from the synovia of day 12 STIA mice following DTx at day 3 and 5 (n=7 964 
mice per group). (g) Number of FAPα expressing cells quantified by flow 965 
cytometry from digested synovia (n=8 mice), popliteal (draining) and 966 
mesenteric (non-draining) lymph nodes (n=6 mice) following IA 967 
administration of DTx into the ankle joint during STIA (harvested day 14) 968 
and (h) daily change in weight from baseline (expressed as percentage of 969 
original body weight) in STIA mice compared to non-arthritic mice (n=6 970 
mice). (i) Effect of local deletion of synovial FAPα expressing cells (by IA 971 
injection of DTx); on ankle joint thickness in the resolving model of STIA 972 
model when compared to the wrist joints on the same mouse (non-deleted 973 
limbs) (n=8 mice) and to non-arthritic DTR+ and DTR- injected mice (n=6 974 
mice per group) with AUC analysis. (j) Representative micro-CT images of 975 
day 14 STIA and non-arthritic control mice following IA injection of DTx and 976 
quantification of bone erosion and new bone formation (STIA DTR- n=10, 977 
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STIA DTR+ n=13, DTR- and DTR+ n=8). (k) Quantification of the number of 978 
fibroblasts and leucocytes in digested synovia of day 9 STIA mice analysed 979 
by flow cytometry following IA administration of DTx (n=8 mice). Statistics: 980 
2-way ANOVA with Tukey’s post hoc a,c,e,h,k, two-tailed paired Student’s 981 
t-test, f,g, 1-way ANOVA with Tukey’s multiple comparison tests, I,j. Data 982 
represented as Mean+S.D., except a,c,e,f,g,k and AUC analysis in I, which 983 
are shown as box plots (centre line, median; box limits, upper and lower 984 
quartiles; whiskers, maximum and minimum values.  985 
 986 
Extended data 4: 10x Chromium single cell RNAseq (droplet based 987 
single cell) analysis of CD45- cell populations from inflamed synovium. 988 
(a) t-SNE projection of non-hematopoietic stromal cells from the inflamed 989 
mouse joint (n=3 biological replicates, day 9 STIA) showing the initial 990 
automatic cluster assignments from Seurat (projection is identical to that 991 
shown in Fig 3a). (b) The same t-SNE plot coloured for biological replicate. 992 
(c) The barplot shows the number of cells in each cluster stratified by 993 
replicate. (d) Cluster cell identification: the five panels of violin plots show 994 
expression (normalised, log-transformed counts of the cells from all of the 995 
n=3 biological replicates, y axes) of known cell type marker genes (for 996 
fibroblasts, lining layer fibroblasts, osteoblasts, chondrocytes, and vascular 997 
cells) in each of the automatically assigned clusters (x axes). The colours of 998 
violin plots correspond to those shown in Extended data Data 4a. 999 
 1000 
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Extended data 5: continued cluster identification analysis. The four 1001 
panels of violin plots show expression (normalised, log-transformed counts 1002 
of the cells from all of the n=3 biological replicates, y axes) of known cell 1003 
type marker genes (for pericytes, muscle cells, erythrocytes and the cell 1004 
cycle) in each of the automatically assigned clusters (x axes). The colours 1005 
of violin plots correspond to those shown in Extended data 4a. 1006 
 1007 
Extended data 6: Differential gene expression between fibroblast 1008 
clusters. The heat map shows the (row-scaled) expression of the top 20 1009 
(by p-value) discovered significant, conserved marker genes for each 1010 
cluster (BH adjusted p-value <0.1 in separate tests of cells from each of the 1011 
n=3 biological replicate samples, two-sided Wilcoxon tests). Each column 1012 
represents a single fibroblast and each row the given gene. The cluster 1013 
identification is indicated for each column. LL: lining layer fibroblasts 1014 
correspond to F5 and are PDPN+ THY1- and SL: sub-lining layer fibroblasts 1015 
correspond to F1-F4 fibroblast subsets and are PDPN+ THY1-.    1016 
 1017 
Extended data 7: Differential gene expression in specific fibroblast 1018 
clusters. (a) A set of violin plots showing gene expression (normalised, log-1019 
transformed counts of the cells from all of the n=3 biological replicates, x 1020 
axes) of additional fibroblast markers in each of the F1-F5 fibroblast 1021 
clusters (y axes) (corresponds to Fig 3b). (b) t-SNE projection of fibroblasts 1022 
from the inflamed mouse joint coloured by replicate (corresponds to Fig 1023 
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3b). (c) A set of violin plots showing gene expression (normalised, log-1024 
transformed counts of the cells from all of the n=3 biological replicates, x 1025 
axes) of known markers for chemokines in each of the F1-F5 fibroblast 1026 
clusters (y axes) (corresponds to Fig 3B). (d) Number of cells in each 1027 
cluster stratified by replicate. 1028 
 1029 
Extended data 8: Trajectory analysis and identification of fibroblast 1030 
subpopulations from human RA patients. (a) The Heatmap shows genes 1031 
most strongly up- or downregulated across the inferred F1-F2-F5 trajectory 1032 
in the mouse fibroblasts from the STIA model (as determined by 1033 
Slingshot14). (b-e) Re-analysis of CEL-Seq2 single-cell RNA-sequencing 1034 
dataset from 20 RA patients15. (b) t-SNE projection of the RA patient 1035 
fibroblasts indicating the automatic cluster assignments from Seurat. (c) 1036 
The sets of violin plots show expression (normalised, log-transformed 1037 
counts, cells from all n=20 RA patients, x axes) of cluster marker genes in 1038 
each of the RA patient fibroblast clusters (y axes). The violin plots are 1039 
grouped into six sets comprising of ‘other markers’ (known markers or 1040 
markers reported by Zhang et al15) or of markers characteristic of each of 1041 
the Hs RA F1-F5 clusters as indicated. (d) The same t-SNE plot as in (a) 1042 
coloured by patient ID. (e) The barplot shows the number of patients 1043 
represented in each assigned cluster.  1044 
 1045 
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Extended data 9: Bulk RNA sequencing of sort purified FAPα 1046 
expressing LL and SL cell populations from the inflamed hind limb 1047 
joints of day 9 STIA mice. (a) Gating strategy for flow cytometry based cell 1048 
sorting from day 9 STIA digested synovia gated on CD45- CD31- live cells. 1049 
Coloured gates correspond to each sort purified population and the 1050 
percentage gated cell population is indicated. (b) Principal components 1051 
analysis (PCA) reveals each population clusters according to either a SL 1052 
phenotype or a LL phenotype. Each dot presents a single biological 1053 
replicate sample and is coloured according to the gating strategy outlined in 1054 
(a). (c) The heat map shows the differential expression of the 50 most 1055 
significant genes (by p value) for each population (BH adjusted p-value 1056 
<0.1) and reveals distinct transcriptional profiles between THY1+ and THY1- 1057 
cell populations. (d) Expression of specific genes RNA sequencing in 1058 
PDPN+ FAPα+ THY1- versus PDPN+ FAPα+ THY1+ sort purified cells. For 1059 
each heatmap a column represents a single biological replicate and 1060 
coloured according to the gating strategy in (a). Biological replicates 1061 
represent cells isolated and purified from the digestion of synovia from the 1062 
hind limbs of a single mouse (n=10 THY1- FAPα+, n=5 THY1- FAPα-, n=6 1063 
THY1+ FAPα- and n=12 THY1+ FAPα+ samples).  1064 
 1065 
Extended data 10: Effect of IA injection of fibroblast subsets. (a) Effect 1066 
on ankle joint thickness of IA injection of 500,000 sort purified PDPN+ 1067 
FAPα+ THY1- (blue) or PDPN+ FAPα+ THY1+ (red) cells into the ankle joint 1068 
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of CIA mice at the first sign of joint inflammation (day 0) compared to 1069 
contralateral sham injected joints (n=8 mice per group). (b) Representative 1070 
images of micro-CT analysis and quantification of bone erosion and new 1071 
bone formation (n=8 mice per group). (c) Flow cytometric analysis of 1072 
leucocytes in the digested synovia of injected joints, 7 days post injection 1073 
(n=8 mice per group). (d) Representative confocal microscopy of ankle joint 1074 
tissue of mice injected with red Tomato expressing PDPN+ FAPα+ THY1- or 1075 
PDPN+ FAPα+ THY1+ isolated from day 9 STIA cells and injected into day 3 1076 
STIA recipient mice (representative images from n=6 mice, 14 days post 1077 
injection). (e) Flow cytometric analysis of digested synovia, 14 days post 1078 
injection of cell trace labelled cells (isolated from day 9 STIA mice and 1079 
injected into the ankle joint of day 3 STIA recipient mice), gated on the 1080 
CD45- CD31- PDPN+ cell fraction. Percentage of THY1+ (red) or THY1- 1081 
(blue) cell in this gated cell fraction is indicated (representative of n=6 per 1082 
group). (f) Percentage of engraftment and viability of injected cells 14 days 1083 
post injection into the ankle joints of STIA mice (n=8 per treatment group, 1084 
two tailed Student’s t-test). Engraftment is expressed as the percentage 1085 
recovery of the original injected cell number. Statistics: 1-way ANOVA with 1086 
Bonferroni post hoc test, b,c and AUC analysis a. Paired two-tailed 1087 
Student’s t-test f. Data represented as Mean+S.D., except c,e and AUC 1088 
analysis in a, which are shown as shown as box plots (centre line, median; 1089 
box limits, upper and lower quartiles; whiskers, maximum and minimum 1090 
values.  1091 
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